Signatera ctDNA testing bridges the gap from uncertainty to actionability by answering clinically meaningful questions at each stage of the patient’s journey. By doing so, ctDNA doesn’t just add another biomarker. It redefines how clinicians navigate the care pathway, moving from reactive to proactive care. The post Signatera™ as a Pan-Cancer Decision-Making Tool to Illuminate the Care Pathway appeared first on Inside Precision Medicine .